Creutzfeldt–Jakob disease (CJD): causes, signs, diagnosis and prevention

Cause and pathological features

CJD results from abnormal forms of the prion protein that induce normally folded proteins to adopt a pathological configuration. These misfolded proteins accumulate in brain tissue, producing neuronal loss, gliosis and the characteristic spongiform change—small vacuoles that give the brain a sponge-like appearance. Brain tissue damage progresses quickly, impairing cognition, coordination and basic bodily functions. Pathologists identify prion-associated protein deposits and the spongiform pattern at autopsy.

Clinical forms and epidemiology

Clinically, CJD is grouped into several types: sporadic (the most common), genetic or familial (caused by inherited PRNP gene variants), iatrogenic (acquired accidentally through medical procedures), and variant CJD (vCJD) linked to exposure to BSE-contaminated material. Sporadic CJD occurs worldwide and is rare—roughly a few cases per million people per year—while familial forms follow inherited patterns and iatrogenic cases are prevented by modern safety measures.

Symptoms, course and diagnosis

Typical early features include rapidly progressive dementia, memory loss, personality change, visual disturbances and impaired coordination. Myoclonus (sudden muscle jerks) and akinetic mutism can appear in advanced stages. Clinicians use clinical assessment plus tests—electroencephalography (EEG), magnetic resonance imaging (MRI), cerebrospinal fluid markers and specialized assays such as RT-QuIC—to support the diagnosis. Cerebrospinal fluid testing for surrogate proteins may assist but is not definitive without neuropathological confirmation.

• Common signs: rapid cognitive decline, ataxia, visual problems, myoclonus.
• Investigations: EEG patterns, MRI changes, CSF biomarkers and prion-specific assays.

Transmission, prevention and management

Prions resist standard sterilization, so strict infection-control protocols are essential where risk exists. Documented iatrogenic transmission has occurred via contaminated neurosurgical instruments, transplanted tissues and historically via cadaver-derived hormones; blood-borne transmission has been reported for variant CJD under rare circumstances. Preventive actions include single-use or validated decontamination of high-risk instruments, donor screening and restrictions designed to lower exposure risk. There is no proven disease-modifying treatment; care focuses on symptom control, supportive and palliative measures.

History and notable facts

The disorder is named after early 20th-century neurologists who described its clinical and pathological features. Public concern about CJD rose in the late 20th century when cases of vCJD were linked to BSE in cattle, prompting public health interventions and major changes in food safety and medical sterilization. Ongoing research aims to improve early detection, clarify mechanisms of prion propagation and develop therapies, but progress is cautious because prion biology and human safety impose significant scientific and ethical constraints.

For further overviews and clinical guidance, see resources on degenerative brain disease, prion biology at prion research pages, diagnostic methods at protein assay references, and public health guidance on containment and instrument sterilization at BSE and variant CJD summaries. Additional background and visual descriptions of tissue changes are available via educational pathology materials at spongiform encephalopathy resources and neuroanatomy references at brain tissue guides. Historical accounts and policy responses can be explored through archives linked from public health timelines and clinical case discussions at medical review pages. For patient support and caregiver information, consult curated help pages shown at support resources.